![Zorbtive [somatropin (rDNA origin) for injection]](images/Zorbtive_180.png)
The potential for less
PN dependence
People with SBS who
were treated with
Zorbtive—a study summary
What some people
experienced after treatment
 |
| “Less time spent on PN might lead to an improved lifestyle.” |
For those people in Group 3, who were treated with Zorbtive® [somatropin
(rDNA origin) for injection] and a special oral diet including glutamine, the results are summarized below.
| Immediately after the 28-day treatment... |
| The amount of parenteral nutrition (PN) people needed was reduced up to 73% on average |
| The number of days people received PN was reduced from 5.4 days per week to one day per week, on average |
| Twelve weeks after the treatment... |
| 25% of people treated were able to eliminate PN completely |
| For many people treated, the reduced level of PN achieved immediately after treatment was maintained (average 73% PN reduction) |
After Zorbtive treatment, many people may need less PN, which may lead to an improved lifestyle.
You and your doctor should decide if Zorbtive treatment is right for you.
Side effects reported
Common side effects for people in the study included fluid retention (swelling) and muscle and joint pain.
Zorbtive treatment was discontinued for several days with some people, due to pain and swelling. Treatment was restarted at one-half dose, with no further problems reported.
People in the study also reported nausea, vomiting, stomach pain and gas, which may have been caused by SBS or by Zorbtive treatment.
The potential for less PN dependence
People with SBS who were treated with Zorbtive—a study summary
What some people experienced after treatment
Frequently asked questions
Home
Zorbtive® [somatropin (rDNA origin) for injection] is indicated for the treatment of Short Bowel Syndrome (SBS) in patients receiving specialized nutritional support. Optimal management of SBS may include dietary adjustments, enteral feedings, parenteral nutrition, and fluid and micronutrient supplements, as needed.
Some common side effects of Zorbtive treatment include muscle and joint pain, and fluid retention (swelling).
Zorbtive may also cause serious side effects such as inflammation of the pancreas (pancreatitis), diabetes or
other blood sugar problems, pain, numbness or tingling in the wrist and hand, or increased blood pressure
in the brain. Make sure and talk with your doctor about these side effects.
Do not take Zorbtive if you have any of the following serious medical conditions: open-heart surgery; stomach-area (abdominal) surgery; an accident; breathing problems (respiratory failure); cancer; or, allergy to Zorbtive or other growth hormone medications.
This information is not intended to replace discussions with your healthcare professional.
For additional information about Zorbtive, please read the Zorbtive Patient Information Leaflet
and Zorbtive Full Prescribing Information and talk to your doctor. You can also call SeroCareSM
toll free at 800-714-2437. Zorbtive is available by prescription only.
This Web site was developed by EMD Serono, Inc. (emdserono.com), makers of Zorbtive, to educate SBS patients
and interested healthcare professionals about this treatment for Short Bowel Syndrome.
This site contains medical information that is intended for residents of the United States
only and is not meant to substitute for the advice provided by a medical professional.
Always consult a doctor if you have health concerns. Use and access of this
site is subject to the terms and conditions as set out in our Legal Statement
and Privacy Policy.
© 2007 EMD Serono, Inc. All rights reserved. 